When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
LNTH - FDA accepts Lantheus' application for prostate cancer imaging agent
Lantheus Holdings Inc.
Under priority review status, the FDA has accepted Lantheus' ([[LNTH]] +3.5%) marketing application for PyL (18F-DCFPyL), a prostate specific membrane antigen-targeted positron emission tomography imaging agent for prostate cancer.Action date has been assigned of May 28, 2021. The FDA has also indicated that it is not currently planning to hold an advisory committee meeting to discuss the application.Marketing application the imaging agent was filed in September.